MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Mar 19, 2025
Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcers
Expanded strategic research collaborations with industry leaders, now including Kerecis
$20 million in revenue for 2024; $24 million projected for 2025; $44 million in cash as of Year-End 2024
